Table 2.
Clinicopathologic characteristics of the primary breast tumors examined in this study: Details of the primary breast tumors in the 18 patients from whom blood alone was evaluated for HER2 by FISH using the OncoCEE™ microfluidic device
| Tumor characteristic | Frequency (n = 18) | Frequency (%) |
|---|---|---|
| Tumor stage | ||
| T4 | 2 | 11.1 |
| T3 | 1 | 5.5 |
| T2 | 3 | 16.6 |
| T1 | 12 | 66.6 |
| Nodal stage | ||
| N3 | 0 | 0 |
| N2 | 0 | 0 |
| N1 | 2 | 11.1 |
| N0 | 16 | 88.8 |
| HER2 status | ||
| HER2+ | 1 | 5.5 |
HER2, human epidermal growth factor receptor 2; FISH, fluorescence in situ hybridization; CEE, cell enrichment and extraction.